Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
Subscribe To Our Newsletter & Stay Updated